British regulatory authority approves Glucophage® Extended Release (XR) for type 2 diabetes patients with moderate renal impairment stage 3a or stable chronic heart failure The approval is based on ...
Janssen R&D announced results from a Phase 3 study on the use of initial combination therapy of canagliflozin and metformin extended release (XR) in type 2 diabetes patients with higher A1C levels and ...
Glucophage mg film tablet, glucophage xr mg tab L. An emerging treatment that may eventually end up as a standard treatment is multiple injections of steroids into the middle ear. Made year, thousands ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved a once-daily, fixed-dose combination therapy of the SGLT2 inhibitor canagliflozin and ...
Non-HbA1c markers useful in monitoring diabetes Patients who forget to take Metformin SR twice daily can be switched to Metformin XR with once daily dosing. Consider changing to the Metformin XR ...
PRINCETON, N.J. & LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) approved KOMBIGLYZE ™ ...
SAN DIEGO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from two 24-week Phase 3 clinical studies examining the investigational ...
Metformin (Bigsens XR (1 gm)) is an oral antidiabetic agent, prescribed for type 2 diabetes. It helps control blood sugar levels. The information provided on this page is intended to serve as a ...
Whitehouse Station, NJ - Merck announced on February 2, 2012 that the US Food and Drug Administration (FDA) has approved Janumet XR (sitagliptin and extended-release metformin hydrochloride) tablets ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback